|
70
|
240
|
4qz7C |
Ycp beta5-a50v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
65
|
233
|
4qwfM |
Ycp beta5-m45i mutant in complex with carfilzomib |
|
57
|
204
|
4qw4I |
Ycp in complex with carfilzomib |
|
59
|
226
|
4qv6H |
Ycp beta5-a49v mutant |
|
68
|
244
|
4qlqB |
Ycp in complex with tripeptidic epoxyketone inhibitor 8 |
|
66
|
233
|
4qwuM |
Ycp beta5-c52f mutant in complex with bortezomib |
|
66
|
233
|
4qwgM |
Ycp beta5-a49v mutant in complex with carfilzomib |
|
70
|
244
|
4qvnB |
Ycp beta5-m45v mutant in complex with bortezomib |
|
64
|
231
|
4qz6E |
Ycp beta5-a49t-a50v double mutant in complex with the epoxyketone inhibitor onx 0914 |
|
59
|
222
|
4qw6L |
Ycp beta5-m45v mutant in complex with carfilzomib |
|
63
|
241
|
4qvyG |
Ycp beta5-a49t-mutant in complex with bortezomib |
|
60
|
222
|
4quxL |
Ycp beta5-a49t-mutant |
|
57
|
222
|
4qz6H |
Ycp beta5-a49t-a50v double mutant in complex with the epoxyketone inhibitor onx 0914 |
|
61
|
195
|
4qw0J |
Ycp beta5-a49t-a50v-double mutant in complex with bortezomib |
|
65
|
231
|
4qzxM |
Ycp beta5-c63f mutant in complex with the epoxyketone inhibitor onx 0914 |
|
70
|
243
|
4qw6F |
Ycp beta5-m45v mutant in complex with carfilzomib |
|
69
|
233
|
4qlqM |
Ycp in complex with tripeptidic epoxyketone inhibitor 8 |
|
71
|
244
|
4r00B |
Ycp beta5-c52f mutant in complex with omuralide |
|
69
|
244
|
4qz2B |
Ycp beta5-m45i mutant in complex with the epoxyketone inhibitor onx 0914 |
|
65
|
241
|
4qluG |
Ycp in complex with tripeptidic epoxyketone inhibitor 9 |
|
59
|
226
|
4qvpH |
Ycp beta5-m45t mutant in complex with bortezomib |
|
58
|
204
|
4qv0I |
Ycp beta5-a49t-a50v-double mutant |
|
68
|
243
|
4r18F |
Ligand-induced lys33-thr1 crosslinking at subunit beta5 of the yeast 20s proteasome |
|
68
|
244
|
4qz5B |
Ycp beta5-a49t-mutant in complex with onx 0914 |
|
71
|
212
|
4qwrK |
Ycp beta5-c52f mutant in complex with carfilzomib |
|
70
|
242
|
4qw0D |
Ycp beta5-a49t-a50v-double mutant in complex with bortezomib |
|
57
|
220
|
4r67I |
Human constitutive 20s proteasome in complex with carfilzomib |
|
56
|
204
|
4qw0I |
Ycp beta5-a49t-a50v-double mutant in complex with bortezomib |
|
69
|
244
|
4qv6B |
Ycp beta5-a49v mutant |
|
59
|
196
|
4qvnN |
Ycp beta5-m45v mutant in complex with bortezomib |
|
64
|
231
|
4r00E |
Ycp beta5-c52f mutant in complex with omuralide |
|
72
|
243
|
4qwsF |
Ycp beta5-c63f mutant in complex with carfilzomib |
|
61
|
196
|
4qv6N |
Ycp beta5-a49v mutant |
|
67
|
250
|
4qzzA |
Ycp in complex with omuralide |
|
70
|
244
|
4qw0B |
Ycp beta5-a49t-a50v-double mutant in complex with bortezomib |
|
70
|
243
|
4qv5F |
Ycp beta5-m45i mutant |
|
57
|
222
|
4qz3H |
Ycp beta5-a49v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
68
|
240
|
4qw7C |
Ycp beta5-m45t mutant in complex with carfilzomib |
|
71
|
243
|
4qv6F |
Ycp beta5-a49v mutant |
|
60
|
196
|
4qltN |
Ycp in complex with tripeptidic epoxyketone inhibitor 2 (pr924) |
|
59
|
222
|
4qzwL |
Ycp beta5-c52f mutant in complex with the epoxyketone inhibitor onx 0914 |
|
72
|
212
|
4qw6K |
Ycp beta5-m45v mutant in complex with carfilzomib |
|
70
|
243
|
4qvqF |
Ycp beta5-m45i mutant in complex with bortezomib |
|
66
|
250
|
4qw1A |
Ycp beta5-a50v mutant in complex with bortezomib |
|
67
|
250
|
4qz1A |
Ycp beta5-m45t mutant in complex with the epoxyketone inhibitor onx 0914 |
|
63
|
195
|
4qvpJ |
Ycp beta5-m45t mutant in complex with bortezomib |
|
62
|
238
|
4r67F |
Human constitutive 20s proteasome in complex with carfilzomib |
|
59
|
226
|
4qw1H |
Ycp beta5-a50v mutant in complex with bortezomib |
|
67
|
233
|
4qv7M |
Ycp beta5-a50v mutant |
|
68
|
242
|
4qz6D |
Ycp beta5-a49t-a50v double mutant in complex with the epoxyketone inhibitor onx 0914 |
